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Occurrence of Yeast Bloodstream Infections 
between 1987 and 1995 in Five Dutch University 
Hospitals
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C.MJ.E. Vandenbroucke-Grauls3, H.A. Verbrugh2, M.C. Vos2, A.Y.L. Weersink5, 
J.A.A. Hoogkamp-Korstanje1, J.F.G.M. Meis1
The aim of this study was to identify retrospectively trends in fungal bloodstream infec­
tions in The Netherlands in the period from 1987 to 1995. Results of over 395,000 blood 
cultures from five Dutch university hospitals were evaluated. Overall, there were more 
than 12 million patient days of care during the nine-year study period. The rate of can­
didemia doubled in the study period, reaching an Incidence of 0.71 episodes per 10,000 
patient days in 1995. The general increase in candldemia was paralleled by an increase 
in non-Candida albicans bloodstream infections, mainly due to Candida glabrata. How­
ever, more than 60% of the infections were caused by Candida albicans. Fluconazole- 
resistant species such as Candida krusei did not emerge during the study period. The 
increasing rate of candidemia found in Dutch university hospitals is similar to the trend 
observed in the USA, but the rate is lower and the increase is less pronounced.
In recent years, Candida species, most notably 
Candida albicans, have emerged as important 
nosocomial pathogens. Over the past decade, the 
incidence of Candida bloodstream infections in­
creased two- to fivefold in teaching hospitals and 
one- to fourfold in non-teaching hospitals in the 
USA (1-3). Candidemia occurs most frequently in 
high-risk patients, such as immunocompromised 
patients with an underlying malignancy or hema­
tological disorder (4,5), severely ill burn-patients,
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and surgical and neonatal intensive care patients 
(5-10). Therefore, the incidence of candidemia is 
highest in tertiary care referral hospitals, with an 
incidence of 5-10 per 10,000 admissions (1). Nos­
ocomial candidemia now accounts for 10-15% of 
all hospital-acquired bloodstream infections in 
hospitals in the USA, Candida thus being among 
the four predominant microorganisms causing 
nosocomial bloodstream infections (1,11). Clear­
ly, candidemia is posing an increasingly serious 
problem in infectious diseases, and has been 
shown to be associated with 57% crude and 38% 
attributable mortality rates (12).
As neither the prevalence nor incidence of noso­
comial fungal bloodstream infections in The 
Netherlands is known, the aim of this study was 
to identify trends in yeast bloodstream infections 
retrospectively in this country by evaluating com­
puterized laboratory and census data from five of 
the eight Dutch university hospitals.
Patients and Methods
Five university hospitals in The Netherlands participated in 
the study, including two hospitals in Amsterdam and one hos­
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Table 1: Overall episodes of yeast bloodstream infections in the study period.
1987 1988 1989 1990 1991 1992 1993 1994 1995 Mean ± SD
Yeasts (n=671)
Overall no 57 48 70 64 73 70 111 78 100 74.6 ±19.9
No. per 10.000 PD 0.40 0.34 0.51 0,46 0.54 0.50 0.82 0.58 0.76 0.55 ±0.16
Candida (n=625)
Overall no 53 45 63 59 67 67 101 75 95 69.4 ± 18.4
No. per 10.000 PD 0.37 0.32 0.46 0.43 0.50 0.48 0.74 0.56 0.72 0.31 ±0.15
Cryptococcus (n=46)
Overall 09 4 3 7 5 6 3 10 3 5 5.1 ± 2.3
No. per 10.000 PD 0.03 0.02 0.05 0.03 0.04 0,02 0,07 0.02 0.04 0.035 ±0.017
pital each in Rotterdam, Utrecht and Nijmegen. The overall 
bed capacity of these five hospitals, which serve as tertiary- 
care referral centres for roughly two-thirds of the population 
of The Netherlands, is approximately 5,500.
Episodes of fungemia were identified retrospectively from mi­
crobiology data systems using computer-generated lists of pa­
tients whose blood cultures yielded yeasts during the period 
from 1 January 1987 to 31 December 1995. All patients admit­
ted to the study hospitals were eligible for enrollment. An epi­
sode of fungal bloodstream infection was defined as at least one 
positive blood culture yielding yeast during a single hospitaliza­
tion period. The number of blood culture sets examined per 
year and the outcomes (negative, positive bacterial, positive fun­
gal) were reported. All microbiological data were taken at face 
value, disregarding the different blood culture and identification 
systems used in the participating hospitals. Between 199! and 
1992 automated blood culture systems were implemented in all 
participating hospitals. None of the hospitals used the lysis cen­
trifugation system. Census data to determine patient days were 
retrieved from the hospital information systems.
Results
During the nine-year study period from 1987 to 
1995, the five university hospitals delivered a to­
tal of 12,353,861 patient days of care, averaging 




Figure 1: Episodes of Candida albicans and non-Candida 
albicans fungemia per 10,000 patient days (PD) in five 
Dutch university hospitals from 1987 to 1995 and the year­
ly use of fluconazole estimated from the nationwide sales fig­
ures for capsules (50, 150 and 200 mg) and vials (100 mg 
and 200 mg).
year. The number of patient days decreased over 
the years (from 1,426,319 in 1987 to 1,322,338 in 
1995). In contrast, the number of admissions 
(118,966 in 1987; 128,864 in 1995), and the num­
ber of blood cultures taken per year (34,450 in 
1987; 49,203 in 1995), increased by 8.3% and 
42.8%, respectively.
The proportion of positive blood cultures (with no 
regard for clinical significance) was 19% ± 2.9% 
(mean ± SD), remaining stable over the years.The 
proportion of positive blood cultures yielding 
yeasts ranged from 3.2% in 1988 to 5.6% in 1993.
Overall, 671 episodes of yeast bloodstream infec­
tions occurred during the study period (Table 1); 
635 episodes (94.6 ± 2.9%) were due to Candida 
species, and 46 episodes (6.8%) were due to 
Cryptococats species.
The rates of yeast bloodstream infections in The 
Netherlands during the study period are given as 
episodes per 10,000 patient days (Table 1). The 
lowest rate was seen in 1988 (0.34 episodes per
10.000 patient days), the highest rate in 1993 
(0.82 episodes per 10,000 patient days). Figure 1 
depicts the individual rates for Candida albicans 
and non-Candida albicans. During the study peri­
od, the rate of bacteremia increased from 15.2 ep­
isodes per 10,000 patient days to 23.5 episodes per
10.000 patient days in 1987 and 1995, respective­
ly. Therefore, all rates showed the same increasing 
trend. Importantly, there was no significant differ­
ence between the rate of candidemia due to 
Candida albicans and non-Candida albicans spe­
cies. During the study period, fluconazole was li­
censed for sale in The Netherlands.'Fire annual use 
of fluconazole, estimated from the nationwide 
sale figures (data supplied by Pfizer,'Hie Nether­
lands), increased by factor four from 15.5 kg in 
1990 to 63.0 kg in 1995 (Figure 1).
The number of episodes of fungemia caused by the 
different Candida species and the proportion due 
to the individual non-Candida albicans species is
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Table 2: Episodes of fungemia caused by individual Candida species and proportion of candidemia due to nor\-Candlda albicans 
species in the study period.
1987 1988 1989 1990 1991 1992 1993 1994 1995
C. albicans 39 32 45 43 42 46 61 46 57
Non-C. albicans
C, glabrata 3 3 5 3 5 2 14 10 16
C. tropicalis 2 1 2 1 3 1 3 4 4
C. krusei 2 1 0 0 1 0 0 2 2
C. parapsllosls 4 1 1 4 2 4 6 2 2
C. guitlermondli 0 1 0 0 1 1 3 1 2
Other species 0 0 1 1 5 4 3 3 3
Not determined* 3 6 9 7 9 9 11 7 9
Subtotal 14 (26%) 13 (29%) 18 (29%) 16 (27%) 26 (38%) 21 (31%) 40 (40%) 29 (39%) 38 (40%)
Total 53 45 63 59 68 67 101 75 95
* Mostly orginating from one study centre that only differentiated C. a/Jh/cansand non-C. albicans species.
shown in Table 2. The increase of non -Candida 
albicans species was mainly due to Candida glab- 
rata. Interestingly, the number of episodes of can­
didemia due to Candida krusei was very low 
throughout the study period (Figure 2). In the last 
year of the study period, 40% of all Candida 
bloodstream infections were due to non -Candida 
albicans species, Candida glabrata accounting for
tient days). Statistically significantly increased 
rates were demonstrated for the four predominant 
blood culture isolates coagulase-negative staphy­
lococci, Staphylococcus aureus, enterococci and 
Candida species. Rates of candidemia increased 
12-fold during the study period, reaching a peak 
of two episodes per 10,000 patient days in 1991 
(16). The rates of bacteremia and candidemia
42% or 55% of those episodes (depending on found in Dutch university hospitals show the
whether the figures for the non-determined spe­
cies were included or not, see Table 2).
Discussion
Major changes have occurred in hospital popula­
tions, health care technology and the use of anti­
microbial drugs during the last two decades. Da­
ta from the National Nosocomial Infections Sur-
same increasing trend, but on a lower scale. In
1991, we found 0.5 episodes of candidemia per
10,000 patient days, a rate fourfold lower than the 
UIHC rate. Even three years after the end of the 
study in the USA, the rate of candidemia in 
Dutch university hospitals is still 2.8-fold lower 
(0.72 episodes per 10,000 patient days). In gener­
al, the rates of candidemia in The Netherlands are 
not only lower but the increase is less dramatic 
(2.3-fold compared to 12-fold at the UIHC). This 
difference between the USA and The Netherlands
veillance System and other hospitals in the USA might be due to the very restricted antibiotic pol-
show that these changes have had a profound im- icy of Dutch physicians both within and outside
pact on the epidemiology of fungal infections, m- the hospital, which is reflected in the low incidence
eluding the increasing incidence of Candida 0f other multi-resistant pathogens, such as penicil-
bloodstream infections (1 ,2 ,13,14). So far, only lin-resistant pneumococci, methicillin-resistant
one European study has addressed the increasing Staphylococcus aureus, and vancomycin-resistant
problem of fungemia. Bruun et al. (15) showed an enterococci (17-19). 
increase in the annual incidence of fungemia at a
Danish university hospital from 19 episodes in 
1989 to 57 episodes in 1994. Unfortunately, the au­
thors gave no rates, thereby making it impossible 
to compare their findings with the literature and 
introducing the possibility of bias due to a likely 
increase in the number of blood cultures taken, as 
demonstrated in our study.
Pittet and Wenzel (16) reported a linear increase 
in the rates of nosocomial bloodstream infections 
at the University of Iowa Hospitals and Clinics 
(UIHC) between 1981 (67 episodes per 10,000 pa­
tient days) and 1992 (184 episodes per 10,000 pa-
MC. giabrata 
a C . krusai
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Figure 2: Occurrence of Candida albicans, Candida glabra­
ta and Candida krusei among blood culture isolates in five 
Dutch university hospitals from 1987 to 1995.
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Overall, 60% of all candidemic episodes in the 
study period were caused by Candida albicans, but 
the proportion of candidemic episodes due to non- 
Candida albicans species increased from 26% to 
40%.This increase was due mainly to a rising num­
ber of episodes due to Candida glabrata, a 
Candida species with reduced susceptibility to flu­
conazole. During the study period, the rates of can- 
didemia due to Candida species with reduced flucon­
azole susceptibility (Candida glabrata and 
Candida krusei) increased 4.7-fold (0.03 per 10,000 
patient days in 1987 versus 0.14 per 10,000 patient 
days in 1995) compared to an 2.8-fold increase 
(0.06 per 10,000 patient days in 1987 versus 0.17 per
10,000 patient days in 1995) for the other non- 
Candida albicans species. However, other factors be» 
sides the increased use of fluconazole in The 
Netherlands may have contributed to this species 
shift and should be identified in future investigations.
Changes in blood culture techniques, most impor­
tantly the introduction of agitation (1991/92), 
may have influenced our general findings, but were 
not the only factors influencing the general trend 
since this would have resulted in a sudden increase 
with only minor changes in the period before and 
after the introduction.
To what degree demographic changes in patient 
population may have contributed to the observed 
trend is not clear. During the study period the 
number of admissions and thus the number of pa­
tients who could develop candidemia increased, 
but at the same time the average time of hospital­
ization decreased (from 12.1 days in 1987 to 10.3 
days in 1995) thereby reducing the chance of the 
individual patient acquiring systemic candidiasis.
The introduction of new diagnostic and therapeu­
tic techniques, and the increased and prolonged 
use of multiple antimicrobial agents in a growing 
proportion of severely ill patients (reflected in the 
growing number of blood cultures taken) may be 
other factors contributing to the increase of nos­
ocomial Candida bloodstream infections in 
Dutch university hospitals.
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